2.63
price up icon1.54%   0.04
pre-market  Pre-market:  2.70   0.07   +2.66%
loading
Acumen Pharmaceuticals Inc stock is traded at $2.63, with a volume of 425.58K. It is up +1.54% in the last 24 hours and down -5.40% over the past month. Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
See More
Previous Close:
$2.59
Open:
$2.66
24h Volume:
425.58K
Relative Volume:
0.56
Market Cap:
$159.31M
Revenue:
-
Net Income/Loss:
$-133.35M
P/E Ratio:
-1.1918
EPS:
-2.2068
Net Cash Flow:
$-123.75M
1W Performance:
-9.93%
1M Performance:
-5.40%
6M Performance:
+77.70%
1Y Performance:
+121.01%
1-Day Range:
Value
$2.60
$2.78
1-Week Range:
Value
$2.52
$3.035
52-Week Range:
Value
$0.8551
$3.60

Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile

Name
Name
Acumen Pharmaceuticals Inc
Name
Phone
617-344-4190
Name
Address
1210-1220 WASHINGTON STREET, NEWTON
Name
Employee
52
Name
Twitter
Name
Next Earnings Date
2026-03-26
Name
Latest SEC Filings
Name
ABOS's Discussions on Twitter

Compare ABOS vs VRTX, REGN, ALNY, ARGX, INSM

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ABOS icon
ABOS
Acumen Pharmaceuticals Inc
2.63 159.31M 0 -133.35M -123.75M -2.2068
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
454.97 115.58B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
749.47 79.23B 14.34B 4.50B 3.77B 41.56
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
328.70 43.59B 3.71B 313.75M 465.38M 2.2571
ARGX icon
ARGX
Argen X Se Adr
697.05 43.26B 4.16B 1.29B 734.26M 19.58
INSM icon
INSM
Insmed Inc
148.31 31.97B 606.42M -1.28B -997.58M -6.403

Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-17-25 Initiated Citigroup Buy
Jul-26-24 Initiated Citigroup Buy
Dec-12-23 Initiated Deutsche Bank Buy
Jul-20-23 Resumed BofA Securities Buy
May-18-23 Initiated Cantor Fitzgerald Overweight
Jul-15-22 Initiated BTIG Research Buy
Jun-30-22 Initiated H.C. Wainwright Buy
Jan-21-22 Upgrade BofA Securities Neutral → Buy
Jul-26-21 Initiated BofA Securities Neutral
Jul-26-21 Initiated Credit Suisse Outperform
Jul-26-21 Initiated Stifel Buy
Jul-26-21 Initiated UBS Buy
View All

Acumen Pharmaceuticals Inc Stock (ABOS) Latest News

pulisher
Mar 24, 2026

Acumen Pharmaceuticals Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView

Mar 24, 2026
pulisher
Mar 23, 2026

Acumen Pharmaceuticals (ABOS) Projected to Post Earnings on Monday - Defense World

Mar 23, 2026
pulisher
Mar 23, 2026

ABOS (Acumen Pharmaceuticals) PB Ratio : 1.74 (As of Mar. 23, 2026) - GuruFocus

Mar 23, 2026
pulisher
Mar 22, 2026

If You Invested $1,000 in Acumen Pharmaceuticals, Inc. (ABOS) - Stock Titan

Mar 22, 2026
pulisher
Mar 21, 2026

Aug Rallies: What hedge funds are buying Acumen Pharmaceuticals IncWeekly Trend Report & Trade Opportunity Analysis - baoquankhu1.vn

Mar 21, 2026
pulisher
Mar 21, 2026

Wall Street Zen Downgrades Acumen Pharmaceuticals (NASDAQ:ABOS) to Sell - MarketBeat

Mar 21, 2026
pulisher
Mar 20, 2026

RA CAPITAL MANAGEMENT, L.P. Increases Stake in Acumen Pharmaceuticals Inc - GuruFocus

Mar 20, 2026
pulisher
Mar 20, 2026

Dip Buying: How does Acumen Pharmaceuticals Inc perform in inflationary periods2026 Intraday Action & Stepwise Trade Signal Implementation - baoquankhu1.vn

Mar 20, 2026
pulisher
Mar 19, 2026

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026 - The Manila Times

Mar 19, 2026
pulisher
Mar 19, 2026

Alzheimer's drug developer Acumen sets March 26 results webcast - Stock Titan

Mar 19, 2026
pulisher
Mar 18, 2026

Acumen Pharmaceuticals Spotlights Sabirnetug Phase II Progress, JCR Brain-Delivery Partnership at Conference - MarketBeat

Mar 18, 2026
pulisher
Mar 18, 2026

RA Capital entities boost Acumen (NASDAQ: ABOS) stake with 6.1M-share grant - Stock Titan

Mar 18, 2026
pulisher
Mar 18, 2026

Acumen Pharmaceuticals at Stifel Forum: Strategic Insights on Alzheimer’s Drug - Investing.com Canada

Mar 18, 2026
pulisher
Mar 18, 2026

ABOS: Phase II Alzheimer's trial for sabirnetug targets late 2026 data, with EBD clinical entry by 2027 - TradingView

Mar 18, 2026
pulisher
Mar 18, 2026

Acumen Pharmaceuticals, Inc. unveils novel antibodies targeting amyloid beta oligomers at ADPD2026 - Traders Union

Mar 18, 2026
pulisher
Mar 18, 2026

Acumen Pharmaceuticals (NASDAQ:ABOS) Stock Price Expected to Rise, BTIG Research Analyst Says - Defense World

Mar 18, 2026
pulisher
Mar 17, 2026

Acumen Pharma Presents Brain Delivery Studies at Alzheimer’s and Parkinson’s Diseases Conference 2026 - Yahoo Finance

Mar 17, 2026
pulisher
Mar 17, 2026

RA Capital boosts Acumen (ABOS) ownership to 29.5% after $20M PIPE buy - Stock Titan

Mar 17, 2026
pulisher
Mar 17, 2026

Acumen Unveils Enhanced Brain Delivery Technology and Latest Alzheimer's Research Findings at International AD/PD Conference - citybiz

Mar 17, 2026
pulisher
Mar 17, 2026

Private placement at Acumen to advance EBD program - BioWorld MedTech

Mar 17, 2026
pulisher
Mar 17, 2026

Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Raised to $8.00 - MarketBeat

Mar 17, 2026
pulisher
Mar 17, 2026

Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer's and Parkinson's Diseases 2026 - Bitget

Mar 17, 2026
pulisher
Mar 17, 2026

Mouse study boosts brain delivery of Acumen’s Alzheimer’s antibody - Stock Titan

Mar 17, 2026
pulisher
Mar 17, 2026

Acumen Raises Capital to Advance Enhanced Brain Delivery - The Globe and Mail

Mar 17, 2026
pulisher
Mar 17, 2026

Dow Update: Whats Acumen Pharmaceuticals Incs historical return2026 Short Interest & Entry and Exit Point Strategies - baoquankhu1.vn

Mar 17, 2026
pulisher
Mar 16, 2026

Institution Moves: Is Acumen Pharmaceuticals Inc a strong candidate for buy and hold2026 Macro Moves & Verified Chart Pattern Trade Signals - baoquankhu1.vn

Mar 16, 2026
pulisher
Mar 16, 2026

Acumen Pharmaceuticals Raises $35.75 Million to Advance Enhanced Brain Delivery Alzheimer’s Therapy with Strong Preclinical Results 1 - Minichart

Mar 16, 2026
pulisher
Mar 16, 2026

Acumen secures funding to advance enhanced brain delivery program - MSN

Mar 16, 2026
pulisher
Mar 16, 2026

Acumen Pharmaceuticals, Inc. announced that it has received $35.749992 million in funding from RA Capital Management, L.P., ADAR1 Capital Management, LLC, Sands Capital Alternatives, LLC and other investors - marketscreener.com

Mar 16, 2026
pulisher
Mar 16, 2026

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio - Bitget

Mar 16, 2026
pulisher
Mar 16, 2026

Acumen Pharmaceuticals Raises $35.75 Million in Private Placement to Fund EBD Program - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

Acumen Pharmaceuticals (NASDAQ: ABOS) secures $35.75M to advance EBD Alzheimer’s program - Stock Titan

Mar 16, 2026
pulisher
Mar 16, 2026

Acumen Pharmaceuticals announces $35.75 million Private Placement to advance potential best-in-class molecules from amyloid beta oligomer-selective enhanced brain delivery portfolio - marketscreener.com

Mar 16, 2026
pulisher
Mar 16, 2026

Acumen Pharmaceuticals Announces $35.75 Million Private Placement To Advance Potential Best-In-Class Molecules From Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio - TradingView

Mar 16, 2026
pulisher
Mar 13, 2026

ABOS SEC FilingsAcumen Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 13, 2026
pulisher
Mar 13, 2026

ABOS Forecast, Price Target & Analyst Ratings | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) - ChartMill

Mar 13, 2026
pulisher
Mar 11, 2026

Team members drive company mission, Acumen Pharmaceuticals, Inc. asserts - Traders Union

Mar 11, 2026
pulisher
Mar 10, 2026

Acumen Pharma chief legal officer sells $6813 in stock By Investing.com - Investing.com Canada

Mar 10, 2026
pulisher
Mar 10, 2026

Acumen (NASDAQ: ABOS) legal chief sells 2,090 shares after option exercise - Stock Titan

Mar 10, 2026
pulisher
Mar 10, 2026

Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - Bitget

Mar 10, 2026
pulisher
Mar 10, 2026

Alzheimer's therapeutics developer joins Stifel 2026 virtual CNS forum - Stock Titan

Mar 10, 2026
pulisher
Mar 10, 2026

Stock Market Recap: What is the earnings history of Acumen Pharmaceuticals Inc2026 Closing Moves & Daily Oversold Bounce Ideas - baoquankhu1.vn

Mar 10, 2026
pulisher
Mar 07, 2026

Highs Report: Is Acumen Pharmaceuticals Inc a turnaround story2025 Fundamental Recap & Expert Verified Movement Alerts - baoquankhu1.vn

Mar 07, 2026
pulisher
Mar 06, 2026

Aug Spikes: What is the earnings history of Acumen Pharmaceuticals Inc2025 Price Action Summary & Real-Time Volume Analysis - baoquankhu1.vn

Mar 06, 2026
pulisher
Mar 06, 2026

Acumen Pharmaceuticals (NASDAQ: ABOS) files Form 144 for insider sale - Stock Titan

Mar 06, 2026
pulisher
Mar 05, 2026

Acumen Pharmaceuticals to Highlight New Alzheimer’s Research Progress at AD/PD™ 2026 - citybiz

Mar 05, 2026
pulisher
Mar 05, 2026

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives $6.80 Consensus Price Target from Analysts - Defense World

Mar 05, 2026
pulisher
Mar 03, 2026

Acumen Pharma chief legal officer Meisner sells $28k in shares - Investing.com Australia

Mar 03, 2026
pulisher
Mar 03, 2026

Acumen (NASDAQ: ABOS) CLO exercises options and sells 9,406 shares - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026 - mx.advfn.com

Mar 03, 2026
pulisher
Mar 03, 2026

Acumen Pharmaceuticals to showcase advances in Alzheimer's treatment at international conference on Alzheimer's and Parkinson's diseases 2026 - marketscreener.com

Mar 03, 2026

Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Acumen Pharmaceuticals Inc Stock (ABOS) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Meisner Derek M
Chief Legal Officer & Corp Sec
Mar 06 '26
Sale
3.26
2,090
6,813
173,999
$27.36
price up icon 1.82%
$47.03
price up icon 3.20%
$53.54
price up icon 4.29%
$88.77
price up icon 2.26%
ONC ONC
$283.45
price up icon 2.81%
$148.31
price up icon 6.59%
Cap:     |  Volume (24h):